Abstract
The problem of curing cancer is steadily coming into sharper focus and the picture emerging is the challenge of dealing with metastatic cancer in new ways. Of the 870,000 new cases of cancer each year, approximately half will be localized at presentation. The majority of these, about 400,000 patients per year, will be cured with either surgery or radiotherapy. The remainder will require some form of systemic therapy, either to prevent recurrence (adjuvant therapy) or to treat actual recurrent disease. Of this number about 50,000 will be cured. The remainder, constituting 50% of patient with cancer, will die. The primary cause of their deaths will be metastases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chabner BA, Fine RL, Allegra CJ, Yeh GC, Curt GA: Cancer chemotherapy: Progress and expectations. Cancer (In press).
Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63: 1727–1733, 1979.
Biedler JF, Peterson PHF: Altered plasma membrane glycoconjugates of Chinese hamster cells with acquired resistance to actinomycin D, daunorubicin and vincristine. IN: Sartorelli AC, Lazlo JS and Bertino JR (eds.) Molecular Actions and Targets for Cancer Chemotherapeutic Agents. Academic Press, New York, pp. 453–482, 1981.
Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multi-drug resistance in mammalian cell lines. Science 221: 1285–1288, 1983.
Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calciun influx blockers. Cancer Res. 43: 2905–2910, 1983.
Wisch JS, Griffin JD, Kufe DW: Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N. Engl. J. Med. 309: 1599–1602, 1983.
Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WP, Salmon SE, Simon RH, Vendetti JM, Von Hoff DD: Application of human tumor colony-forming assay to new drug screening. Cancer Res. (In press).
Curt GA, Clendeninn NJ, Chabner BA: Drug resistance in cancer. Cancer Treat. Rep. 68: 87–99, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Chabner, B.A. (1986). Present Status and Future Prospects for Treatment of Metastatic Cancer. In: Honn, K.V., Powers, W.E., Sloane, B.F. (eds) Mechanisms of Cancer Metastasis. Developments in Oncology, vol 40. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2635-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2635-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9646-1
Online ISBN: 978-1-4613-2635-9
eBook Packages: Springer Book Archive